Length of hospital stay in treatment of venous thromboembolism: Do outcomes vary preference of anticoagulant? A retrospective analysis
Abstract
Introduction: Regarding the choice of novel or traditional oral anticoagulants for the treatment of different entities of venous thromboembolism (VTE), there is contrasting, little or no evidence to put forward. We here assess the impact of various anticoagulants in reducing the length of stay (LOS) in patients with acute VTE. Objectives was: 1. To compare LOS among novel and traditional anticoagulants groups on discharge. 2. To determine the clinical risk factors responsible for lengthier hospital stay in patients having acute VTE. Material and methods: We conducted a retrospective data analysis of 161 consecutively admitted patients in the Life line Hospital, Karachi, Pakistan with a recent diagnosis of VTE. Lengths of stay with various anticoagulants on discharge were compared. Bleeding complications and readmission outcomes were compared, along with determination of independent predictors by multivariate analysis for LOS among groups. Results: Patients discharged on a vitamin K antagonist (warfarin) had significantly longer hospital stay compared to patients on rivaroxaban (7.65 days vs. 5.21 days, p < 0.001). Patients discharged exclusively on enoxaparin (hospital stay duration of 3.30 days) or on a combination of enoxaparin and warfarin (hospital stay duration of 4.26 days,) when compared for LOS to rivaroxaban, showed statistical significance (p < 0.0001). Conclusions: Warfarin has significant longer LOS compared to rivaroxaban. Bleeding outcomes and readmissions compared among anticoagulant discharged groups were found to be statistically insignificant. Novel anticoagulants have an observable impact on the length of hospital stay in patients with acute venous thromboembolism.
Keywords: venous thromboembolismpulmonary embolismrivaroxabanenoxaparinwarfarin
References
- Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost. 2017; 83(05): 657–660.
- Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006; 21(7): 722–727.
- Heit J, Cohen A, Anderson F, et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005; 106(11): 910–910.
- Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353(9162): 1386–1389.
- Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e419S–e496S.
- Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011; 62: 41–57.
- Ramacciotti E, Agati LB, Calderaro D, et al. EINSTEIN Investigators, EINSTEIN–PE Investigators, EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
- Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14): 1287–1297.
- Prins MH, Lensing AWa, Bauersachs R, et al. EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11(1): 21.
- van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014; 30(5): 829–837.
- Bookhart BK, Haskell L, Bamber L, et al. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ. 2014; 17(10): 691–695.
- Kahler ZP, Beam DM, Kline JA. Cost of treating venous thromboembolism with heparin and warfarin versus home treatment with rivaroxaban. Acad Emerg Med. 2015; 22(7): 796–802.
- American College of Radiology. Practical guidelines and standards for performance of the peripheral venous ultrasound examination. Reston 2015.
- van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006; 295(2): 172–179.
- Ghaye B, Remy J, Remy-Jardin M. Non-traumatic thoracic emergencies: CT diagnosis of acute pulmonary embolism: the first 10 years. Eur Radiol. 2002; 12(8): 1886–1905.
- Gulsun M, Goodman LR, Washington L, et al. CT for thromboembolic disease. Radiol Clin North Am. 2002; 40(4): 751–771.
- Desai A, Desai A, Calixte R, et al. Comparing length of stay between patients taking rivaroxaban and conventional anticoagulants for treatment of venous thromboembolism. Lung. 2016; 194(4): 605–611.
- Ruggles DR, Freyman RL, Oxenham AJ. Influence of musical training on understanding voiced and whispered speech in noise. PLoS One. 2014; 9(1): e86980.
- Saint CA, Castelli MR, Crannage AJ, et al. Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Med. 2017; 5: 2050312117719628.
